drugset / Trial / NCT04616677

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

NCT04616677

Phase 1 Completed 24 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetic of a single oral dose of JNJ-42847922 in adult participants with renal impairment compared with healthy participants with normal renal function.

Timeline

Start
2021-03-31
Primary completion
2022-10-18
Completion
2022-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule Oral